Advanced search
Publication Cover
International Journal of Nanomedicine Volume 18, 2023 - Issue
Submit an article Journal homepage
536
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Functional Peptide-Loaded Gelatin Nanoparticles as Eyedrops for Cornea Neovascularization Treatment

Ya-Chun Chu1 Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City, Taiwan;2 Department of Chemical Engineering and Biotechnology, National Taipei University of Technology, Taipei City, TaiwanView further author information
,
Hsu-Wei Fang2 Department of Chemical Engineering and Biotechnology, National Taipei University of Technology, Taipei City, Taiwan;3 Institute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Miaoli County, TaiwanView further author information
,
Yu-Yi Wu1 Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City, TaiwanView further author information
,
Yu-Jun Tang1 Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City, TaiwanView further author information
,
Erh-Hsuan Hsieh1 Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City, TaiwanView further author information
,
YiZhou She4 School of Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City, TaiwanView further author information
,
Che-Yi Chang1 Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City, TaiwanView further author information
,
I-Chan Lin5 Department of Ophthalmology, Wan Fang Hospital, Taipei Medical University, Taipei City, Taiwan;6 Department of Ophthalmology, School of Medicine, College of Medicine, Taipei Medical University, Taipei City, TaiwanView further author information
,
Yin-Ju Chen1 Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City, Taiwan;7 Department of Radiation Oncology, Taipei Medical University Hospital, Taipei City, Taiwan;8 International Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City, Taiwan;9 Center for Precision Medicine and Translational Cancer Research, Taipei Medical University Hospital, Taipei City, TaiwanView further author information
,
Guei-Sheung Liu1 Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City, Taiwan;10 Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC, Australia;11 Ophthalmology, Department of Surgery, University of Melbourne, East Melbourne, VIC, Australia;12 Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, AustraliaORCID Iconhttps://orcid.org/0000-0003-3379-724XView further author information
ORCID Icon &
Ching-Li Tseng1 Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City, Taiwan;8 International Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City, Taiwan;9 Center for Precision Medicine and Translational Cancer Research, Taipei Medical University Hospital, Taipei City, Taiwan;13 Research Center of Biomedical Device, College of Biomedical Engineering, Taipei Medical University, Taipei City, TaiwanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9446-4030View further author information
ORCID Icon show all
Pages 1413-1431 | Received 23 Nov 2022, Accepted 07 Mar 2023, Published online: 23 Mar 2023

References

  • Zhang C, Yin Y, Zhao J, et al. An update on novel ocular nanosystems with possible benefits in the treatment of corneal neovascularization. Int J Nanomedicine. 2022;17:4911–4931. doi:10.2147/IJN.S375570
  • Britton Anna K, Crayford Basil B. Resolution of refractory corneal neovascularization with subconjunctival bevacizumab. Case Rep Ophthalmol. 2020;11:652–657. doi:10.1159/000510114
  • Sharif Z, Sharif W. Corneal neovascularization: updates on pathophysiology, investigations & management. Romanian J Ophthalmol. 2019;63:15–22. doi:10.22336/rjo.2019.4
  • Nicholas MP, Mysore N. Corneal neovascularization. Exp Eye Res. 2021;202:108363. doi:10.1016/j.exer.2020.108363
  • Brunner M, Romano V, Steger B, et al. Imaging of corneal neovascularization: optical coherence tomography angiography and fluorescence angiography. Invest Ophthalmol Vis Sci. 2018;59:1263–1269. doi:10.1167/iovs.17-22035
  • Hsu C-C, Chang H-M, Lin T-C, et al. Corneal neovascularization and contemporary antiangiogenic therapeutics. J Chin Med Assoc. 2015;78:323–330. doi:10.1016/j.jcma.2014.10.002
  • Roshandel D, Eslani M, Baradaran-Rafii A, et al. Current and emerging therapies for corneal neovascularization. Ocul Surf. 2018;16(4):398–414. doi:10.1016/j.jtos.2018.06.004
  • Al-Debasi T, Al-Bekairy A, Alkatheri A, Al Harbi S, Mansour M, Albekairy A. Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization. Saudi J Ophthalmol. 2017;31(2):99–105. doi:10.1016/j.sjopt.2017.02.008
  • Barry Z, Park B, Corson TW. Pharmacological potential of small molecules for treating corneal neovascularization. Molecules. 2020;25(3468):1–40. doi:10.3390/molecules25153468
  • Feizi S, Azari A, Safapour S. Therapeutic approaches for corneal neovascularization. Eye Vision. 2017;4(28):1–10. doi:10.1186/s40662-017-0094-6
  • Rojas M, Lemtalsi T, Toque H, et al. NOX2-induced activation of arginase and diabetes-induced retinal endothelial cell senescence. Antioxidants. 2017;6(43):1–13. doi:10.3390/antiox6020043
  • Khayrullina G, Bermudez S, Byrnes K. Inhibition of NOX2 reduces locomotor impairment, inflammation, and oxidative stress after spinal cord injury. J Neuroinflammation. 2015;12:172. doi:10.1186/s12974-015-0391-8
  • Singh PK, Saadi A, Sheeni Y, Shekh-Ahmad T. Specific inhibition of NADPH oxidase 2 modifies chronic epilepsy. Redox Biol. 2022;58:102549. doi:10.1016/j.redox.2022.102549
  • Hu CG, Wu ZF, Huang ZH, et al. Nox2 impairs VEGF-A-induced angiogenesis in placenta via mitochondrial ROS-STAT3 pathway. Redox Biol. 2021;45:102051. doi:10.1016/j.redox.2021.102051
  • Ucgul RK, Celebi S, Yilmaz NS, Bukan N, Ucgul AY. Intrastromal versus subconjunctival anti-VEGF agents for treatment of corneal neovascularization: a rabbit study. Eye. 2021;35(11):3123–3130. doi:10.1038/s41433-020-01347-3
  • Fraunfelder FT. Chapter 2 - Ocular drug delivery and toxicology. In: Fraunfelder FFT, Fraunfelder FRW, editors. Drug-Induced Ocular Side Effects. 8th ed. London: Elsevier; 2021:3–11.
  • Loftsson T. Topical drug delivery to the retina: obstacles and routes to success. Expert Opin Drug Deliv. 2022;19(1):9–21. doi:10.1080/17425247.2022.2017878
  • Tian B, Bilsbury E, Doherty S, et al. Ocular drug delivery: advancements and Innovations. Pharmaceutics. 2022;14(9):1931. doi:10.3390/pharmaceutics14091931
  • Srividya G, Rapalli VK, Waghule T, et al. Nanocarriers for ocular drug delivery: current status and translational opportunity. RSC Adv. 2020;10:27835–27855. doi:10.1039/D0RA04971A
  • Joseph R, Venkatraman S. Drug delivery to the eye: what benefits do nanocarriers offer? Nanomedicine. 2017;12:683–702. doi:10.2217/nnm-2016-0379
  • Mun E, Morrison P, Williams A, Khutoryanskiy V. On the barrier properties of the cornea: a microscopy study of the penetration of fluorescently labeled nanoparticles, polymers, and sodium fluorescein. Mol Pharm. 2014;11:3556–3564. doi:10.1021/mp500332m
  • Zimmer A, Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev. 1995;16:61–73. doi:10.1016/0169-409X(95)00017-2
  • Yadav T, Jat RK. Microspheres as an ocular drug delivery system – a review. J Drug Deliv Therap. 2013;3:114–123. doi:10.22270/jddt.v3i1.343
  • Nagarwal R, Kant S, Singh P, Maiti P, Pandit J. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release. 2009;136:2–13. doi:10.1016/j.jconrel.2008.12.018
  • Zhu S, Gong L, Li Y, Xu H, Gu Z, Zhao Y. Safety assessment of nanomaterials to eyes: an important but neglected issue. Adv Sci. 2019;6(16):1802289. doi:10.1002/advs.201802289
  • Mobaraki M, Soltani M, Zare Harofte S, et al. Biodegradable nanoparticle for cornea drug delivery: focus review. Pharmaceutics. 2020;12(12):1–26. doi:10.3390/pharmaceutics12121232
  • Sahoo N, Sahoo R, Biswas N, Guha A, Kuotsu K. Recent advancement of gelatin nanoparticles in drug and vaccine delivery. Int J Biol Macromol. 2015;81:317–331. doi:10.1016/j.ijbiomac.2015.08.006
  • Yasmin R, Shah M, Khan S, Ali R. Gelatin nanoparticles: a potential candidate for medical applications. Nanotechnol Rev. 2017;6:191–207. doi:10.1515/ntrev-2016-0009
  • Huang H-Y, Wang M-C, Chen Z-Y, et al. Gelatin–epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief. Int J Nanomedicine. 2018;13:7251–7273. doi:10.2147/IJN.S173198
  • Chuang YL, Fang HW, Ajitsaria A, et al. Development of Kaempferol-loaded gelatin nanoparticles for the treatment of corneal neovascularization in mice. Pharmaceutics. 2019;11(635):1–16. doi:10.3390/pharmaceutics11120635
  • Coester C, Langer K, Briesen H, Kreuter J. Gelatin nanoparticles by two step desolvation - A new preparation method, surface modifications and cell uptake. J Microencapsul. 1999;17:187–193.
  • Ofokansi K, Winter G, Fricker G, Coester C. Matrix-loaded biodegradable gelatin nanoparticles as new approach to improve drug loading and delivery. Eur J Pharm Biopharm. 2010;76(1):1–9. doi:10.1016/j.ejpb.2010.04.008
  • Kalyanaraman B, Darley-Usmar V, Davies K, et al. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. Free Radic Biol Med. 2012;52:1–6. doi:10.1016/j.freeradbiomed.2011.09.030
  • Wang J-H, Tseng C-L, Lin F-L, et al. Topical application of TAK1 inhibitor encapsulated by gelatin particle alleviates corneal neovascularization. Theranostics. 2022;12:657–674. doi:10.7150/thno.65098
  • World Health Organization. Blindness and vision impairment; 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment. Accessed March 10, 2023.
  • Tseng C-L, Chen K-H, Su W-Y, Lee Y-H, Wu -C-C, Lin F-H. Cationic gelatin nanoparticles for drug delivery to the ocular surface: in vitro and in vivo evaluation. J Nanomater. 2013;2013:1–11. doi:10.1155/2013/238351
  • Rey F, Cifuentes-Pagano E, Kiarash A, Quinn M, Pagano P. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O2− and systolic blood pressure in mice. Circ Res. 2001;89:408–414. doi:10.1161/hh1701.096037
  • Li Z, Gu L. Effects of mass ratio, pH, temperature, and reaction time on fabrication of partially purified pomegranate ellagitannin-gelatin nanoparticles. J Agric Food Chem. 2011;59:4225–4231. doi:10.1021/jf200024d
  • Ahsan S, Rao C. The role of surface charge in the desolvation process of gelatin: implications in nanoparticle synthesis and modulation of drug release. Int J Nanomedicine. 2017;12:795–808. doi:10.2147/IJN.S124938
  • Vinjamuri BP, Papachrisanthou K, Haware R, Chougule M. Gelatin solution pH and incubation time influences the size of the nanoparticles engineered by desolvation. J Drug Deliv Sci Technol. 2021;63:102423. doi:10.1016/j.jddst.2021.102423
  • Zhang T, Yu Z, Ma Y, Chiou B-S, Liu F, Zhong F. Modulating physicochemical properties of collagen films by cross-linking with glutaraldehyde at varied pH values. Food Hydrocoll. 2022;124:107270. doi:10.1016/j.foodhyd.2021.107270
  • Slusarewicz P, Zhu K, Hedman T. Kinetic characterization and comparison of various protein crosslinking reagents for matrix modification. J Mater Sci Mater Med. 2010;21(4):1175–1181. doi:10.1007/s10856-010-3986-8
  • Solanki P, Sajwan R. Gelatin nanoparticles as a delivery system for proteins. J Nanomed Res. 2015;2:18–20. doi:10.15406/jnmr.2015.02.00018
  • Potapovitch A, Suhan T, Shutava T, Kostyuk V. Receptor-mediated endocytosis is an important way for gelatin nano-particles penetration into cells. J Belarusian State Univ Biol. 2020;3–10. doi:10.33581/2521-1722-2020-1-3-10
  • Cifuentes-Pagano E, Meijles DN, Pagano PJ. The quest for selective nox inhibitors and therapeutics: challenges, triumphs and pitfalls. Antioxid Redox Signal. 2014;20(17):2741–2754. doi:10.1089/ars.2013.5620
  • DelBaugh R, Chen Q, Devine I, et al. Nox2ds-Tat, A Peptide Inhibitor of NADPH Oxidase, exerts cardioprotective effects by attenuating reactive oxygen species during ischemia/reperfusion injury. Am J Biomed Sci. 2016;8:208–227.
  • Hachisuka H, Dusting G, Abberton K, Morrison W, Jiang F. Role of NADPH oxidase in tissue growth in a tissue engineering chamber in rats. J Tissue Eng Regen Med. 2008;2:430–435. doi:10.1002/term.115
  • Xia C, Meng Q, Liu L-Z, Rojanasakul Y, Wang X-R, Jiang B-H. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res. 2007;67:10823–10830. doi:10.1158/0008-5472.CAN-07-0783
  • Chan E, Wijngaarden P, Liu G-S, Jiang F, Peshavariya H, Dusting G. Involvement of Nox2 NADPH oxidase in retinal neovascularization. Invest Ophthalmol Vis Sci. 2013;54:7061–7067. doi:10.1167/iovs.13-12883
  • Fukai M. Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovasc Res. 2006;71:226–235. doi:10.1016/j.cardiores.2006.04.015
  • Bedard K, Krause K-H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245–313. doi:10.1152/physrev.00044.2005
  • Tsai C-H, Wang P-Y, Lin IC, Huang H, Liu G-S, Tseng C-L. Ocular drug delivery: role of degradable polymeric nanocarriers for ophthalmic application. Int J Mol Sci. 2018;19(2830):1–20. doi:10.3390/ijms19092830
  • Castro B, Fulgêncio G, Domingos L, Cotta O, Silva-Cunha A, Fialho S. Positively charged polymeric nanoparticles improve ocular penetration of tacrolimus after topical administration. J Drug Deliv Sci Technol. 2020;60:101912. doi:10.1016/j.jddst.2020.101912
  • Des Rieux A, Fievez V, Garinot M, Schneider Y-J, Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006;116:1–27. doi:10.1016/j.jconrel.2006.08.013
  • Li Q, Dinculescu A, Shan Z, et al. Downregulation of p22phox in retinal pigment epithelial cells inhibits choroidal neovascularization in mice. Mol Ther. 2008;16:1688–1694. doi:10.1038/mt.2008.164
  • Vogel J, Kruse C, Zhang M, Schröder K. Nox4 supports proper capillary growth in exercise and retina neo-vascularization: nox4 in exercise. J Physiol. 2015;593:2145–2154. doi:10.1113/jphysiol.2014.284901
  • Wilkinson-Berka J, Deliyanti D, Rana I, et al. NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy. Antioxid Redox Signal. 2014;20:2726–2740. doi:10.1089/ars.2013.5357
  • Gu X-J, Liu X, Zhao Y, et al. Involvement of NADPH oxidases in alkali burn-induced corneal injury. Int J Mol Med. 2016;38:75–82. doi:10.3892/ijmm.2016.2594
  • Chan E, Wijngaarden P, Chan E, et al. NADPH oxidase 2 plays a role in experimental corneal neovascularisation. Clin Sci. 2016;130:683–696.
  • Dastjerdi M, Sadrai Z, Saban D, Zhang Q, Dana R. Corneal penetration of topical and subconjunctival Bevacizumab. Invest Ophthalmol Vis Sci. 2011;52:8718–8723. doi:10.1167/iovs.11-7871
  • Huang L, Gao H, Wang Z, Zhong Y, Hao L, Du Z. Combination nanotherapeutics for dry eye disease treatment in a rabbit model. Int J Nanomedicine. 2021;16:3613–3631. doi:10.2147/IJN.S301717
  • Brandes R. A radical adventure: the quest for specific functions and inhibitors of vascular NAPDH oxidases. Circ Res. 2003;92:583–585. doi:10.1161/01.RES.0000066880.62205.B0
  • Fukai M. VEGF signaling through NADPH oxidase-derived ROS. Antioxid Redox Signal. 2007;9:731–739. doi:10.1089/ars.2007.1556
  • Fukai T, Fukai M. Cross-talk between NADPH oxidase and mitochondria: role in ROS signaling and angiogenesis. Cells. 2020;9:1849. doi:10.3390/cells9081849
  • Zuo L, Fan Y, Wang F, Gu Q, Xu X. A SiRNA targeting vascular endothelial growth factor- A inhibiting experimental corneal neovascularization. Curr Eye Res. 2010;35:375–384. doi:10.3109/02713681003597230
  • Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res. 2000;70:419–428. doi:10.1006/exer.1999.0790

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.